On April 5th, the 22nd Century Group (XXII) signed a three-year exclusive licensing and distribution agreement with global cannabis company Cookies. The agreement covers all non-Delta-9 THC cannabis-derived consumer products of the Cookies brand, including the procurement of all raw materials and APIs, as well as the production and retail distribution of e-cigarettes and other CBD products. In the past three years, the 22nd Century Group's GVB Biopharma has already produced various Cookies products. With this new agreement, they will continue to produce Cookies' leading products and are expected to account for more than half of Cookies' non-Delta-9 THC sales.
The agreement also involves the integration of market sales and distribution, utilizing 22nd Century's senior consumer packaged goods sales team, who plan to distribute Cookies products in up to 18 markets to launch the company's innovative VLN product in 2023. The consumer goods sales team will target around 60,000 retail stores, including independent retailers, discount tobacco outlets, and e-cigarette shops in non-entertainment states, serviced by their top regional distributors and chain discount tobacco store networks. The product will also be available for sale on Cookies' e-commerce website.
22nd Century Group, Inc. is a biotech company focused on altering the nicotine content in tobacco plants and the cannabinoid content in cannabis plants through genetic engineering, gene editing, and modern plant breeding. Its primary goal in the tobacco industry is to introduce cigarettes with 95% less nicotine than traditional cigarettes in the US and international markets.
References:
22nd Century has agreed to a partnership with Cookies.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
